Editor-in-Chief, 23rd March 2017
|
|
- Pearl Brown
- 6 years ago
- Views:
Transcription
1 Author s response to reviews Title: Single Use and Conventional Bronchoscopes for Broncho alveolar Lavage (BAL) in research: A comparative study (NCT ) Authors: Seher Raza Zaidi (seher.zaidi@lstmed.ac.uk) Andrea Collins (andreamcollins@yahoo.com) Elena Mitsi (elena.mitsi@lstmed.ac.uk) Jesús Reiné (jesus.reine@lstmed.ac.uk) Kayleigh Davies (kayleigh.davies@rlbuht.nhs.uk) Angela Wright (a.d.wright@liverpool.ac.uk) Jessica Owugha (jessica.owugha@lstmed.ac.uk) Richard Fitzgerald (richard.fitzgerald@rlbuht.nhs.uk) Amitava Ganguli (a.ganguli@liverpool.ac.uk) Stephen Gordon (stephen.gordon@lstmed.ac.uk) Daniela Ferreira (daniela.ferreira@lstmed.ac.uk) Jamie Rylance (jamie.rylance@lstmed.ac.uk) Version: 1 Date: 03 Apr 2017 Author s response to reviews: Editor-in-Chief, 23rd March 2017 BMC Pulmonary Medicine Dear Editor, Thank you for your letter dated February 21st 2017, regarding our manuscript entitled Single Use and Conventional Bronchoscopes for Broncho alveolar Lavage (BAL) in research: A comparative study (NCT )" (PULM-D ). We have now addressed all your
2 referees comments and revised the manuscript accordingly (see point-by-point answers and changes below). The authors Editor s comments 1. Please amend the statement in the "Consent for publication" section. This consent refers to consent for publication of potentially-identifying information of participants or patients. If your manuscript contains any individual person s data in any form (including individual details, images or videos), consent to publish must be obtained from that person, or in the case of children, their parent or legal guardian. Please provide details of this consent in this section. If your manuscript does not contain any individual person s identifiable data or information, please state Not applicable under this section. ANSWER: Thank you, we have changed this to read as not-applicable. 2. Please provide the trial registration information at the end of the abstract, as per our submissionguidelines. Trial registration: If your article reports the results of a health care intervention on human participants, it must be registered in an appropriate registry and the registration number and date of registration should be in stated in this section. If it was not registered prospectively (before enrolment of the first participant), you should include the words 'retrospectively registered'. See our editorial policies for more information on trial registration ANSWER: Thank you, we have added this at the end of the abstract. 3. Figures should be provided as separate files, and each figure of a manuscript should be submitted as a single file. Each figure is now attached as a separate file, with no legends in these as per the instructions. ANSWER: Thank you, we have added this, as per to the submission guidelines. 4. Please provide figure titles/legends under a separate heading of 'Figure Legends' after the References. If Figure titles/legends are within the main text of the manuscript, please move them. Figure files should contain only the image/graphic, as well as any associated keys/annotations. If titles/legends are present within the figure files, please remove them. ANSWER: Completed. We have moved the figure legends from the main manuscript to the end after the references as requested.
3 Reviewer 1: This article describes the use of disposable bronchoscopes in the research setting. One of the major concerns I have is that the comparison group is not described in the methods or results section other than statics related to BAL yield. Detailed comments are below. ABSTRACT In the background section I would change sentence "... and may also carry a small risk of cross infection" to "... and carries a small risk of cross infection." since bronchoscopy is known to have a risk of infection. In the results section and whole of paper, please change p value to two decimal places. ANSWER: We have changed this to read as carries a small risk of infection The p values were up to two decimal places for total cell yield and cell viability, and the volume yield has now been changed to read as <0.01. Thank you PAPER BACKGROUND 1)The first sentence "flexible fibre optic bronchoscopy" is incorrect. For the last decade, most countries have been using video bronchoscopes and fibre optic scopes are relics of third world medicine. Change to just flexible bronchoscopy. Answer: Thank you, this now reads as flexible bronchoscopy. 2) Line 20 reword to "...of various diffuse lung diseases (3-7). It is used in early phase drug development studies and has a proven safety record in both research and clinical application. BAL is easily performed and well-tolerated with rare complications (8-10)." ANSWER: Thank you, we have changed as described above. 3) Page 2 Line 43 reword to "... bronchoscopes with regard to BAL volumes, cell yield and viability using each method." ANSWER: Thank you, we have re worded this as suggested. RECRUITMENT AND BRONCHOSCOPY We are given no details of the comparison group in this study. Who are they --- age? number? Health status? Were these healthy volunteers also or did they have underlying lung disease that may affect BAL yields and cell #s. The authors need to either include this information for the reader to make an educated comparison or admit comparison all together and report only on the health volunteers and the disposable scopes.
4 ANSWER: Completed. We have added the gender demographics of the healthy controls with comparison between the two groups. DISCUSSION Line is reference 8 correct? The sentence reads like data presentation but the reference is a video of BAL technique. ANSWER: Thank you, this is from our unpublished data and we have removed this sentence from the manuscript. Some of the values used for comparison from conventional bronchoscope, are from this unpublished data. The reference was to the video link which demonstrates our technique. Reviewer 2: Overall a well-done and necessary trial. It is clear that the AmbuScope can generate a slightly higher ml yield of BALF and has the same %viability of cells. The disposable single/use scope could prove overall less expensive since there is less infrastructure involved in its use. There was a higher proportion of males in the AmbuScope group than the conventional bronchoscopy group. This should be explained. In particular, there is some suggestion that the slightly larger airways of equivalently sized males may have a slightly larger airway diameter which would in turn suggest the possibility of improved yield. I suggest that an extra table that breaks out relative yield of disposable vs conventional BAL by gender be shown to demonstrate that there is no gender bias influencing the results. ANSWER: We have looked at these values for all the participants separating by gender, and did not find a difference. Overall the volume yield is similar. This has been observed in other studies as well. I have attached a reference for a study describing this(1). This has also been added to manuscript. Female Median (IQR) Male Median (IQR) BAL Volume Yield Combined 128ml ( ) 127.5ml ( ) In the interest of Open Access, many journals suggest the publication of the de identified individual data set on line. That would be helpful to the scientific community. Answer: Thank you, the data in the format of an excel sheet, along with the accepted article will be available via the online repository of Liverpool School of Tropical Medicine. This can be accessed using the link below:
5 Cell counts were demonstrated, which is important in the evaluation of inflammatory response from a cellular level. However, there is interest in demonstrating BALF supernatant cytokine data (e.g. LTC4, IL4, etc). This paper would be much strengthened if assays of both conventional and AmbuScope BALF was analysed for at least one cytokine. It would have to be a nonpathologic one since these are all healthy volunteers. Alternatively, the authors may be considering a separate submission to address the issues of a variety of cytokine that use a variety of different techniques for measurement (HPLC, DFA, Antibody-electrophoresis, etc). ANSWER: Thank you we will consider submitting such a publication, and have therefore not elaborated on this within the current manuscript. Thank you Your Sincerely Authors If improvements to the English language within your manuscript have been requested, you should have your manuscript reviewed by someone who is fluent in English. If you would like professional help in revising this manuscript, you can use any reputable English language editing service. We can recommend our affiliates Nature Research Editing Service ( and American Journal Experts ( for help with English usage. Please note that use of an editing service is neither a requirement nor a guarantee of publication. Free assistance is available from our English language tutorial ( and our Writing resources ( These cover common mistakes that occur when writing in English Editorial Policies Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript. In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Pulmonary Medicine must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web page for information regarding the criteria for each sub-section (
6 Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections. For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below). Declarations - Ethics approval and consent to participate - Consent to publish - Availability of data and materials - Competing interests - Funding - Authors' Contributions - Acknowledgements Further information about our editorial policies can be found at the following links: Ethical approval and consent: Availability of data and materials section: 1. Olsen HH, Grunewald J, Tornling G, Sköld CM, Eklund A. Bronchoalveolar Lavage Results Are Independent of Season, Age, Gender and Collection Site. PLoS ONE. 2012;7(8):e43644.
ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION
1 ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1. The Brazilian Archives of Cardiology (Arq Bras Cardiol) is a monthly publication of the Brazilian
More informationARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION
ARQUIVOS BRASILEIROS DE CARDIOLOGIA (BRAZILIAN ARCHIVES OF CARDIOLOGY) GUIDELINES FOR PUBLICATION 1. The Brazilian Archives of Cardiology (Arq Bras Cardiol) is a monthly publication of the Brazilian Society
More informationAdis Journals Overview
Adis Journals Overview Introduction Adis Rapid Publishing Service Life after publication AdisOnline.com The Adis publishing heritage The Adis Journals brand has evolved over 40 years to become synonymous
More informationGetting Published: What Journal Editors Really Want
Getting Published: What Journal Editors Really Want Edward Abraham M.D. Professor and Chair, Department of Medicine University of Alabama at Birmingham Presenter Disclosures Edward Abraham M.D. Personal
More informationResearch and publication ethics
Illustration inspired by the work of Chien Shiung Wu Research and publication ethics Stephanie Boughton, Research Integrity Group 24.05.2018 1 Housekeeping Rules To keep the technical process simple, we
More information07/30/2013. Record of Revisions IRB Page 1 of 17
Current Protocol Version 7.1 (Continuing Review) Approved July 30, 2013 Version 7.1 (Amendment) September 6, 2012 Version 7.0 (Continuing Review) July 30, 2012 Version 6.0 (Continuing Review) July 30,
More informationEuropean Stroke Journal: Declaration Guidelines for Authors
Table of Contents 1. Human Research and In Vitro Studies... 2 Required Declarations... 2 Example of a completed declarations section... 2 Example of text that should be used if any declaration is not relevant
More informationJournal of Clinical Urology (JCU): Declaration Guidelines for Authors
Table of Contents 1. Case Report or Case Series... 2 Required Declarations... 2 Example of a completed declarations section:... 2 Example of text that should be used if any declaration is not relevant
More informationUnpacking the evidence behind the AMWA EMWA ISMPP Joint Position Statement. Paul Farrow DPhil CMPP MedComms Networking Brunch Club 5 April 2017
Unpacking the evidence behind the AMWA EMWA ISMPP Joint Position Statement Paul Farrow DPhil CMPP MedComms Networking Brunch Club 5 April 2017 Paul Farrow DPhil CMPP Communications Director at Oxford PharmaGenesis
More informationJeffrey W. Elias, PhD UCD SOM Office of Research Grants Facilitation.
NIH IS CHANGING/ENHANCING THE REVIEW CRITERIA AND FOCUSING ON MISSING OPPORTUNITIES TO EXAMINE SEX DIFFERENCES JOURNALS ARE CHANGING/ENHANCING THE REVIEW CRITERIA Jeffrey W. Elias, PhD UCD SOM Office of
More informationGuide for Authors. Journal scope and general principles
European Annals of Allergy and Clinical Immunology ISSN: 1764-1489 Guide for Authors Journal scope and general principles European Annals of Allergy and Clinical Immunology is a bimonthly peer-reviewed
More informationData & Materials Sharing Agreement. Collaboration for AIDS Vaccine Discovery. Clinical Trials Data Sharing Addendum & Related Information
Data & Materials Sharing Agreement Collaboration for AIDS Vaccine Discovery Clinical Trials Data Sharing Addendum & Related Information I. Overview of this Document The primary purpose of this document
More informationEditor Guidelines. Ethics Approval and Informed Consent Statements
Editor Guidelines Ethics Approval and Informed Consent Statements Editor Guidelines: Ethics Approval and Informed Consent Statements The inclusion of ethics approval and informed consent statements is
More informationANZCTR Framework, challenges and immediate future
ANZCTR Framework, challenges and immediate future Professor Lisa Askie ANZCTR Manager Director, Systematic Reviews & Heath Technology Assessment The University of Sydney Page 1 Background and context The
More informationManuscript Submission Guidelines: Health Services Research and Managerial Epidemiology
Manuscript Submission Guidelines: Health Services Research and Managerial Epidemiology 1. Open Access 2. Peer Review Policy 3. Article Types 4. Publication Fees 5. Authorship 6. How to submit your manuscript
More informationTowards Greater International Transparency of Clinical Trials
Karmela Krleza-Jeric,MD, M.Sc., D.Sc. CIHR - IRSC Towards Greater International Transparency of Clinical Trials Short Term Efforts for Long Term Benefits: CIHR trial policy 2010 1 Outline Prospective trial
More informationAuthor Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document
MELBOURNE CHILDREN S TRIALS CENTRE (MCTC) Guideline document title: Developing, amending and complying with research protocols Version: 2.0 Author: Melbourne Children s Trials Centre (MCTC) Author Signature:
More informationEverything You Wanted to Know About ClinicalTrials.gov*
Everything You Wanted to Know About * Deborah A. Zarin, MD Director, National Library of Medicine (*But Were Afraid to Ask) DISCLAIMER Views are mine and do not necessarily represent views of NIH or HHS
More informationHow journals can help to make clinical trials honest, useful, and usable
How journals can help to make clinical trials honest, useful, and usable Special session on sharing IPD from clinical trials: ICTMC/SCT conference May 2017 Liverpool Dr Trish Groves tgroves@bmj.com twitter
More informationJune 14, To the World Medical Association Secretariat:
June 14, 2013 To the World Medical Association Secretariat: The following are the comments from the Executive Committee of the Latin American and Caribbean Network of Bioethics UNESCO 1 to the draft of
More informationRegulatory and ethical requirements in medical device studies. Finland
Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationLearning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationHow to write and publish a scientific paper (in English)
How to write and publish a scientific paper (in English) Thomas Ferkol, MD Alexis Hartmann Professor of Pediatrics Professor of Cell Biology and Physiology Washington University School of Medicine President
More informationCHANGES IN STUDY PROCEDURES OR FUNDING: IS A NEW STUDY NEEDED?
CHANGES IN STUDY PROCEDURES OR FUNDING: IS A NEW STUDY NEEDED? PROTOCOL REVISIONS, FUNDING, AND SECONDARY ANALYSIS CONSIDERATIONS Emory University IRB August 10, 2017 Topics to be covered When you are
More informationExternal IRB Review What Does it Mean for Your Institution
External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA
More informationClinical Trials: Registration, Results Reporting, and Data Sharing
Clinical Trials: Registration, Results Reporting, and Data Sharing Jerry Sheehan Assistant Director for Policy Development National Library of Medicine National Institutes of Health OECD Expert Workshop
More informationProfessional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study
Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study William Gattrell, Sally Hopewell, Kate Young, Paul Farrow, Richard White, Elizabeth
More informationClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
More information11. Type of Research * Type of research maybe: 1. Biomedical research: research conducted primarily in lab setting
Definition of Data elements required for submission to NMRR * Indicates data is required for submission # Fields * Definition Title, Identification and Study organization 1. Research Title * Research official
More informationHow to write and publish a paper
How to write and publish a paper December 2018 Adrian Aldcroft, Editor in Chief, BMJ Open Writing research papers and using reporting guidelines Resources IMRaD Writing style Research to Publication rtop.bmj.com
More informationBackground: ClincalTrials.gov and the database for Aggregate Analysis of ClincalTrials.gov (AACT)
Background: ClincalTrials.gov and the database for Aggregate Analysis of ClincalTrials.gov (AACT) Background! What is ClinicalTrials.gov?! ClinicalTrials.gov history! Key reporting requirements! Rationale
More informationPOLICY AND PROCEDURE MANUAL
POLICY AND PROCEDURE MANUAL PBRC: POLICY NO. 378.00 ORIGIN DATE: 5/25/2016 IMPACTS: CLINICAL RESEARCH LAST REVISED: 1/1/2017 SUBJECT: SOURCE: PURPOSE PENNINGTON BIOMEDICAL CLINICALTRIALS.GOV POLICY INSTITUTIONAL
More informationStandard Operating Procedures
Standard Operating Procedures 6.0 Protocol development History Version Date Author Reason 1.1 10 th Jan 2006 Contributing New procedure authors 1.2 25 th Feb 2007 S Whicker Administrative update 1.3 11
More informationhttps://dev.e-irb.jhmi.edu/eirb2/sd/resourceadministration/project/printsmartforms?proje...
Print: - *EXTERNAL IRB APPLICATION - TEST* Page 1 of 10 Date: Tuesday, June 13, 2017 4:29:22 PM Print Close 1 - General Information ID: 1. * Principal Investigator: Click Select to choose PI: 2. * Will
More informationAims and challenges of clinical trial data sharing
Aims and challenges of clinical trial data sharing Facilitating data access to non-industry funded research UCL and Yale meeting: 9 October 2015 London Dr Trish Groves Head of research,
More informationJoint statement on public disclosure of results from clinical trials
Joint statement on public disclosure of results from clinical trials Signatories on 18 May 2017 European Commission for Horizon 2020 Societal Challenge Health Demographic Change and Wellbeing (joined on
More informationWMA Declaration of Helsinki Ethical Principles f or Medical Research Involving Human Subjects
WMA Declaration of Helsinki Ethical Principles f or Medical Research Involving Human Subjects Note: Modifications and insertions highlighted and compared to previous 2008 wording by Gillian Vale, Administrator,
More informationClinicalTrials.gov REGISTRATION REQUIREMENTS
ClinicalTrials.gov REGISTRATION REQUIREMENTS Background: What is it? ClinicalTrials.gov is a public registry that provides easy access to information on clinical studies, both clinical trials and observational
More informationMicroRNA mimicry blocks pulmonary fibrosis
EMBO Molecular Medicine Peer Review Process File - EMM-2013-03604 MicroRNA mimicry blocks pulmonary fibrosis Rusty L. Montgomery, Guoying Yu, Paul A. Latimer, Christianna Stack, Kathryn Robinson, Christina
More information10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.
Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov
More informationClinicalTrials.gov. Topics
ClinicalTrials.gov Federal Demonstration Partnership Meeting September 2018 Rebecca J. Williams, Pharm.D., MPH Acting Director, ClinicalTrials.gov National Library of Medicine https://clinicaltrials.gov
More informationClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationSPARK Recruitment Process Document
Last Updated: July 25, 2017 Overview: SPARK SPARK Recruitment Process Document What is SPARK? SPARK (Simons Foundation Powering Autism Research for Knowledge) is a landmark autism research project with
More informationThe Role and Importance of Clinical Trial Registries & Results Databases
The Role and Importance of Clinical Trial Registries & Results Databases Deborah A. Zarin, M.D. Director, ClinicalTrials.gov April 2016 http://clinicaltrials.gov 1 Outline Background Current Policies About
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationHow is trial registration affecting gjournals?
How is trial registration affecting gjournals? Dr Trish Groves Deputy editor, BMJ & Editor in chief, BMJ Open My competing interests Roles at BMJ contributing to, publicising, and leading implementation
More informationCompetent federal higher authority ("Bundesoberbehörde- BOB")
Nutrition/InterventionaI - GERMANY Competent authority Contact Details Contact Name 1 Competent federal higher authority ("Bundesoberbehörde- BOB") Contact Name 2 Federal Institute for Drugs and Medical
More informationMarch 23, Francis S. Collins, M.D., Ph.D Director, National Institutes of Health 9000 Rockville Pike Bethesda, Maryland 20892
March 23, 2015 Francis S. Collins, M.D., Ph.D Director, National Institutes of Health 9000 Rockville Pike Bethesda, Maryland 20892 Re: Clinical Trials Registration and Results Submission [NIH-2011-0003-0003]
More informationExtraction of lotus fibres from lotus stems under microwave irradiation
Extraction of lotus fibres from lotus stems under microwave irradiation Cheng Cheng, Ronghui Guo, Jianwu Lan and Shouxiang Jiang Article citation details R. Soc. open sci. 4: 170747. http://dx.doi.org/10.1098/rsos.170747
More informationClinical trials patient-education brochure
Released November 2005 Revised January 2008 Revised March 2012 Revised July 17, 2017 Clinical trials patient-education brochure Roslyn Mannon, MD David Rothstein, MD Maria Luisa Alegre, MD, PhD Giorgio
More information1.0 Abstract. Palivizumab P Study Results Final
1.0 Abstract Title: Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis
More informationHuman Research Protection Program Guidance for Human Research Determination
Human Research Protection Program Guidance for Human Research Determination I.1.A The sole purpose of the Institutional Review Board (IRB), as defined in federal statutes, is the protection of human subjects
More informationSunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners. Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd
Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd Disclaimer As an independent consultant, the views expressed
More informationDIRECTOR v BAYER. Clinical trial disclosure (Xofigo) CASE AUTH/2908/11/16
CASE AUTH/298//6 DIRECTOR v BAYER Clinical trial disclosure (Xofigo) A study published online in Current Medical Research & Opinion (CMRO) on 25 November 26 was entitled Clinical trial transparency update:
More informationThe patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationTitle: Clinical factors associated with a Candida albicans Germ Tube Antibody (CAGTA) positive test in ICU patients
Author's response to reviews Title: Clinical factors associated with a Candida albicans Germ Tube Antibody (CAGTA) positive test in ICU patients Authors: Javier Pemán (peman_jav@gva.es) Rafael Zaragoza
More informationThe Johns Hopkins Institute for Clinical and Translational Research
ICTR The Johns Hopkins Institute for Clinical and Translational Research INTRODUCTION TO CLINICALTRIALS.GOV LINDA POST, RN, BSN, CCRP RESEARCH NAVIGATOR JUNE 28, 2013 Development of this resource was supported
More informationJonathan Davis, MD Vice-Chair of Pediatrics, Floating Hospital for Children at Tufts Medical Center, Boston, MA Chair, Neonatal Advisory Committee,
Jonathan Davis, MD Vice-Chair of Pediatrics, Floating Hospital for Children at Tufts Medical Center, Boston, MA Chair, Neonatal Advisory Committee, Office of the Commissioner, FDA 2 Informed Consent Consent
More information'Health, demographic change and well-being' Clinical Studies
Cornelius Schmaltz, Head of Unit Health Directorate DG Research and Innovation European Commission 'Health, demographic change and well-being' Clinical Studies Clinical Studies Why? What? Template Essential
More informationNOTICE. Subject: Stakeholders suggestions/comments on Clinical Trials conductance in India
NOTICE Dated: 28.07.2014 Subject: Stakeholders suggestions/comments on Clinical Trials conductance in India During the briefing on CDSCO, Hon ble Minister of Health & Family Welfare desired that there
More informationA SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN
A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical
More informationISPE Comments on the CIOMS 2006 draft Special Ethical Considerations for Epidemiologic Research 1
Epidemiologic Research 1 December 12, 2006 Comments on 2006 CIOMS draft Special Ethical Considerations for Epidemiologic Research as proposed supplement to the updated 2002 CIOMS International Ethical
More informationKathy O Kane Kreutzer, M.Ed., Office of Faculty Affairs, School of Medicine March, 2017
SOM Authorship Guidelines, Recent Updates to the ICMJE Uniform Requirements for Scholarship, and the Emerging Role of Social Media in Monitoring Scholarship Kathy O Kane Kreutzer, M.Ed., Office of Faculty
More informationPublication planning and guidelines
Publication planning and guidelines Elizabeth Wager PhD Sideview liz@sideview.demon.co.uk Publication planning Publishing other people s data (keeping everybody happy) Understanding medical journals Keeping
More informationRegulatory and ethical requirements in medical devices studies. France
Regulatory and ethical in medical devices studies France SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationApril 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
More informationCompliance Department RESEARCH COMPLIANCE MEMORANDUM
Compliance Department RESEARCH COMPLIANCE MEMORANDUM To: UCD Health Chairs & Chief Administrator Officers From: Nirali Patel, Compliance Manager Kathy Olson, Research Compliance Analyst Re: Department
More informationInvestigational Medicinal Product (IMP) Management Standard Operating Procedure
Reference Number: UHB 040 Version Number: 3 Date of Next Review: 26 Apr 2019 Previous Trust/LHB Reference Number: T 363 Standard Operating Procedure Introduction and Aim This procedure is written to support
More informationQuestions and Answers
Status: 30.03.20 20/S 46-074222: Editing and proofreading of documents drafted in English and related services Questions and Answers Below are the questions submitted by candidates together with the respective
More informationWMA Declaration of Helsinki - Ethical
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Download the PDF file Adopted by the 18 th WMA General Assembly, Helsinki, Finland, June 1964 and amended
More informationSWOG
SWOG http://swog.org Page 1 of 5 pages Original Release Date: May 2007 Departments Affected: All Revision Date: May 2014 POLICY ON ADVERTISING FOR SUBJECT RECRUITMENT AND TRIAL PROMOTION When Federal human
More informationRegulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials
Nutrition - LUXEMBOURG Competent authority Contact Details Contact Name 1 Ministry of Health Phone +352 247-85592 / 96 Fax +352 24795615 Email General info@ ms.etat.lu Address Allée Marconi - Villa Louvigny
More informationAntibody against Chikungunya virus (mrna-1944)
Antibody against Chikungunya virus (mrna-1944) Modality Program # Program Indication Preclinical development Phase 1 Phase 2 Phase 3 and commercial Moderna rights mrna-1944 Antibody against Chikungunya
More informationHow To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup
How To Design A Clinical Trial Statistical Analysis Andrew Embleton PhD student/medical Statistician MRC Clinical Trials Unit at UCL At what points do you need to consider statistics? At what points do
More informationScientific journal editor core competencies
Scientific journal editor core competencies My disclosures Founding editor-in-chief, Systematic Reviews On the editorial board of several biomedical journals BMC Medicine Advisory member International
More informationA. TRIAL IDENTIFICATION
PROTOCOL INFORMATION ON A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE CONDUCTED IN A THIRD COUNTRY (i.e. a country outside of the EEA) Note: To ensure consistency the numbering of this form is
More information21 Dec Dear Dr. Halford,
21 Dec 2016 Dear Dr. Halford, I am writing to you in regards to manuscript FVL 2016 0132 entitled "Genital herpes meets its match: a live HSV 2 ICP0 virus vaccine that succeeds where subunit vaccines have
More informationDEFINING BEST PRACTICE FOR ADVERSE EVENT REPORTING WITH INDUSTRY-SPONSORED CLINICAL TRIAL MANUSCRIPTS
11TH ANNUAL MEETING OF ISMPP DEFINING BEST PRACTICE FOR ADVERSE EVENT REPORTING WITH INDUSTRY-SPONSORED CLINICAL TRIAL MANUSCRIPTS April 28, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL
More informationRegulatory and ethics bodies involved in approval process for trials. National Ethics Committee; Agency for Data Protection;
Nutrition/InterventionaI - LUXEMBOURG Competent authority Contact Details Contact Name 1 Ministry of Health Phone +352 247-85592 / 96 Fax +352 24795615 Email General info@ ms.etat.lu Address Allée Marconi
More information1. The confounder information is based on company-based job exposure matrix only with no published information on its validity.
Author s response to reviews Title: Cumulative exposure to shift work and sickness absence: associations in a five-year historic cohort Authors: Alwin van Drongelen (a.vandrongelen@vumc.nl;) Cécile Boot
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More informationInformation for clinical researchers on transparency of clinical trial reporting
Information for clinical researchers on transparency of clinical trial reporting This document has been produced by leading UK healthcare organisations including the medical Royal Colleges and senior representatives
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/CT 5.2 Final
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More informationReporting Checklist for Nature Neuroscience
Corresponding Author: Manuscript Number: Manuscript Type: Chay T. Kuo NNA47008 Article Reporting Checklist for Nature Neuroscience # Main Figures: 7 # Supplementary Figures: 11 # Supplementary Tables:
More informationRegulatory and ethical requirements in medical devices studies. Portugal
Regulatory and ethical in medical devices studies Portugal SECTIONS A.Type of research H. Data Protection SECTIONS A.Type of research H. Data Protection We have differentiated 8 types of research: Medical
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationAmarex Clinical Research Washington DC metro area A Product Development Services Company. From Lab to Market Approval
Amarex Clinical Research Washington DC metro area A Product Development Services Company Regulatory Strategy From Lab to Market Approval Strategy Implementation Pre-Clinical Assays Global Clinical Trials
More informationActing Deputy Commissioner for Operations, U.S. Food and Drug Administration
Available on FDA website at: http://www.fda.gov/newsevents/testimony/ucm113266.htm Pediatric Clinical Trials for Anti-depressant Drug Products Statement of Janet Woodcock, M.D. Acting Deputy Commissioner
More informationBecoming Aware of the Requirements Surrounding Clinical Trial Disclosure (ClinicalTrials.gov)
Becoming Aware of the Requirements Surrounding Clinical Trial Disclosure (ClinicalTrials.gov) Office of Research Compliance and Quality Assurance Yolanda P. Davis Sr. Research Compliance Officer Author:
More informationPHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use
PHV-3 Version 4 - Non-Interventional Post-Authorisation Safety Studies of Medicinal Products for Human Use This guideline replaces PHV-3 guideline version 3 effective from 11. 01. 2016 The guideline provides
More informationCanadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines
Canadian Cancer Clinical Trials Network Portfolio Eligibility Criteria and Guidelines 1. Introduction The Canadian Cancer Clinical Trials Network (3CTN) will support a portfolio of academic clinical trials
More informationNot My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center
Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center Office of Research Compliance and Quality Assurance Yolanda P. Davis Sr. Research Compliance Officer Author: Yolanda P.
More informationGuiding Principles on the Sharing of Clinical Trial Data. DNDi POLICIES
Guiding Principles on the Sharing of Clinical Trial Data DNDi POLICIES May 2017 I. Preamble DNDi s vision is to improve the quality of life and health of people suffering from neglected tropical diseases
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationInstitutional Review Board. Ensuring that the rights and welfare of participants in research are protected.
Institutional Review Board Ensuring that the rights and welfare of participants in research are protected. Michael Linke, PhD, CIP Presenters Health Science Officer, Veterans Affairs Medical Center Associate
More informationIRB USE ONLY Approval Date: September 10, 2013 Expiration Date: September 10, 2014
Approval : September 10, 2013 Expiration : September 10, 2014 DESCRIPTION: You are invited to donate your excess sperm and/or testicular biopsy material, as well as your somatic cells (ordinary body cells
More information